Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report

Introduction Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Several novel therapeutic strategies have been developed to prolong survival patients with advanced HCC. However, decision-making biomarkers owing extensive heterogeneity Next-generation sequencing (NGS) generally used in treatment decisions help benefit from genome-directed targeting. Case presentation A 56 year-old male type-B hepatitis for more than 20 years was admitted our department and underwent laparoscopic left lateral hepatic lobectomy hepatocellular carcinoma. Unfortunately, tumor recurred 1 year later. Despite multiple treatments, continued progress invaded patient’s 5th thoracic vertebras, leading hypoesthesia hypokinesia below nipple line plane 2 NGS revealed MET amplification, crizotinib, an inhibitor MET, recommended. After administration a month, marker levels decreased, shrunk. The patient has remained remission since that time. Conclusions We report high amplification benefited its inhibitor, which recommended by NGS. This indicates potential clinical decision support value satisfactory effect inhibitors.